Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
21 August, 2017 04:28 IST
Zydus receives USFDAs final nod for Eletriptan HCl tablets
Source: IRIS | 19 Jun, 2017, 10.32AM
Comments  |  Post Comment

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Eletriptan Hydrobromide Tablets, 20 mg (base) and 40 mg (base).

The drug which is used in the treatment of migraine will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 7.15, or 1.36%, to trade at Rs 532.55. The total volume of shares traded was 33,144 at the BSE (10.24 a.m., Monday).



Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Vishal Sikka resigns as MD & CEO of Infosys - 18-Aug-2017 12:12
HDFC Bank revises interest rates on saving bank accounts - 18-Aug-2017 11:42
Srei Equipment Finance plans to dilute upto 25% of capital - 18-Aug-2017 11:36
Power Grid to invest Rs 19.31 bn for power transmission related project - 18-Aug-2017 11:30
Infosys in association with ATP unveils new PlayerZone - 18-Aug-2017 11:26
Raymond acquires Ansel's stake in JV entity 'JK Ansell' - 18-Aug-2017 10:24
Piramal Enterprises' arm acquires 100% stake in Context Matters - 17-Aug-2017 10:03
Karnataka Bank ventures into social media presence - 17-Aug-2017 10:00
L&T to divest entire stake in L&T Cutting Tools for Rs 1.74 bn - 17-Aug-2017 09:46
PTC India Financial Services inks MoU with IIFCL Projects - 17-Aug-2017 09:38
EESL and IOCL, BPCL & HPCL sign MOUs for distribution of energy efficient appliances - 17-Aug-2017 08:46
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer